<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01515397</url>
  </required_header>
  <id_info>
    <org_study_id>HC-G-H-0904</org_study_id>
    <nct_id>NCT01515397</nct_id>
  </id_info>
  <brief_title>Comparison of Two Gelatine Solutions</brief_title>
  <official_title>Efficacy and Safety of a Balanced Gelatine Solution in Combination With a Balanced Electrolyte Solution Versus a Standard Gelatine Solution in Combination With a Non-balanced Electrolyte Solution in Patients Scheduled for Abdominal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Melsungen AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of volume replacement is to compensate a reduction in the intravascular volume e.g.
      during surgery and to counteract hypovolemia in order to maintain hemodynamics and vital
      functions. To achieve this, different plasma substitutes are available: Albumin, dextran,
      hydroxyethylstarches and gelatine. The aim of this study is to demonstrate that acid-base
      alterations during elective abdominal surgery can be reduced by the use of a new gelatine
      solution.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>base excess [mmol/l]</measure>
    <time_frame>Change from baseline at end of surgery, an expected average of 2 hours surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>chloride [mmol/l]</measure>
    <time_frame>Change from baseline at end of surgery, an expected average of 2 hours surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>arterial blood gase analyses</measure>
    <time_frame>until 12 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>coagulation status</measure>
    <time_frame>until 12 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function</measure>
    <time_frame>until 12 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>until 12 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemodynamics (systolic and diastolic blood pressure)</measure>
    <time_frame>until 12 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time on ventilation</measure>
    <time_frame>until 12 hours after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hypovolemia</condition>
  <arm_group>
    <arm_group_label>balanced gelatine solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>isotonic colloidal volume substitute</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-balanced gelatine solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>colloidal volume substitute</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gelofusine balanced</intervention_name>
    <description>Gelofusine balanced combined with Sterofundin ISO</description>
    <arm_group_label>balanced gelatine solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gelofusine 4%</intervention_name>
    <description>Gelofusine 4% combined with NaCl 0.9%</description>
    <arm_group_label>non-balanced gelatine solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Male or female patients &gt;= 18 years of age and &lt;= 90 years of age. Women of child
             bearing potential must test negative on standard pregnancy test.

          -  Patients scheduled to undergo elective abdominal surgery (e.g. Rectal resection, liver
             resection, open bowl resection, duodenopancreatectomy reconstitution).

          -  Scheduled intraoperative volume requirement of at least 15 ml / kg body weight (BROCA)
             gelatine solution

          -  Provision of voluntary consent to participate in the study, following a full
             explanation of the nature and purpose of the study, by signing the informed consent
             form approved by the Institutional Ethics Committee (IEC) prior to all evaluations.

        Exclusion:

          -  Patients of ASA-class &gt; III

          -  Known hypersensitivity to gelatine or to any of the constituents of the solution

          -  Patients treated with other colloid solutions and / or blood products 24 hours prior
             to surgery

          -  Patients on hemodialysis

          -  Patients suffering from decompensated renal function (i.e. serum creatinine &gt; 3.0
             mg/dl)

          -  Patients suffering from Hypervolemia Hyperhydration Severe blood coagulation disorders
             Hypernatremia (serum(Na+) &gt; 150 mmol/L) Hyperchloremia (serum(Cl-) &gt; 110 mmol/L)

          -  Estimated perioperative need for blood products of 3,5 ml / kg body weight (BROCA)

          -  Lactation period

          -  Simultaneous participation in another clinical trial

          -  Emergencies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gernot Marx, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Aachen,Klinik für Operative Intensivmedizin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen, Klinik für Anästhesiologie</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Frankfurt/Main</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2012</study_first_submitted>
  <study_first_submitted_qc>January 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <last_update_submitted>November 26, 2013</last_update_submitted>
  <last_update_submitted_qc>November 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypovolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Polygeline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

